Indications for treatment

We aim to improve the treatment of neonatal pulmonary hypertension because we observe a strong unmet clinical needs faced by those newborns and their families. The use of iNO (inhaled NO) treatment is not widely adapted due to the shortcomings of the inhalation machine and the lack of convenience and precision of the instrument. Our strategy is to use our cutting-edge technology to develop a portable NO generator that provides faster and smarter bedside NO delivery system by combining our patented NO generation technology and NO slow-release control technology. This will help patients of pulmonary hypertension to gain a better life quality. We are developing two portable NO generators to treat two rare life-threatening diseases: idiopathic pulmonary arterial hypertension (IPAH) and pulmonary fibrosis. In the near future, we expect to realize NO’s wound healing, antibacterial and antithrombotic effects to create a NO therapy for diabetic foot.

Pulmonary Hypertension(PH)

Pulmonary hypertension refers to a hemodynamic and pathophysiological state in which pulmonary artery pressure rises above a certain threshold, which can lead to right heart failure. It can be an independent disease or a complication. Primary pulmonary hypertension refers to infants with no pulmonary hypertension without obvious cardiopulmonary disease. There are many reasons for secondary pulmonary hypertension, mainly including pulmonary vasoconstriction, erythrocytosis-high viscosity syndrome, pulmonary artery smooth muscle hypertrophy, and reduced pulmonary vascular bed cross-sectional area.

Pulmonary Fibrosis(PF)

Pulmonary fibrosis is a chronic disease. When the lung is injured, the lung secretes collagen to repair it. This will cause a large increase in fibrocytes, and slowly pulmonary fibrosis will form. Patients will have symptoms of difficulty breathing, coughing, and chest tightness and shortness of breath. For fibrosis of the lungs, active treatment should be taken to control the development of the disease.

It is conservatively estimated that the number of patients with idiopathic pulmonary fibrosis is currently around 500,000, and the number of cases continues to increase. This disease is more common among the elderly, with a slightly higher incidence of males than females, and its natural course varies widely and cannot be predicted. The survival rate of IPF patients is worrying. The 5-year survival rate is worse than some tumors, only 30% to 50%.

Diabetic foot

The foot is a target organ for diabetes, a complex, multi-system disease. Diabetic patients with excessively high mechanical pressure due to peripheral neuropathy and peripheral vascular disease can cause damage and deformity of the soft tissues of the feet and bone and joint systems, which in turn can cause a series of foot problems, from mild neurological symptoms to severe ulcers , Infections, vascular diseases, Charcot arthropathy and neuropathic fractures. If active treatment cannot fully resolve the symptoms and complications of the lower extremities, it will cause disastrous consequences.

The incidence of diabetic foot is as high as 8.1% in diabetic patients over 50 years old in China. It is estimated that there is one amputation of diabetic patients every 20 seconds in the world; the annual mortality rate of patients with diabetic foot ulcers is as high as 11%,and the mortality rate of amputated patients is as high as 22%; One third of medical expenses. Diabetic foot is one of the main causes of disability and death of diabetic patients, and it is also a major public health problem that causes a heavy burden on society.

Solution to infection and thrombosis issues for interventional medical device

With advances in medical technology, various minimally invasive and interventional therapies have broken through the bottleneck and become routine treatments. However, if the intervening material is left and moved in the blood vessel, it will increase the mechanical friction, damage the endothelium of the blood vessel, and cause the platelets to aggregate at the tip of the catheter and the damaged part, which is prone to clot and blockage. The study found that indwelling for more than 72-96h is prone to catheter-related hematogenous infections such as phlebitis. For example, the infection rate of implant-related breast reconstruction and breast augmentation surgery is 1%-35%. Long-term infection may cause gradual large cell lymphoma associated with breast implants.
The current countermeasures are antibacterial coatings, and the most common are antibiotics or silver ion materials, but the side effects of heavy metal deposition are obvious. New polymer antibacterial materials are needed to solve such problems.